Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

AIDS

Volumn 15, Issue 10, 2001, Pages 1261-1268

  Martinez E ^a   Blanco, J L ^a   Arnaiz, J A ^a   Perez Cuevas J B ^a   Mocroft, A ^a   Cruceta, A ^a   Marcos, M A ^a   Milinkovic, A ^a   Garcia Viejo M A ^a   Mallolas, J ^a   Carne X ^a   Phillips, A ^a   Gatell, J M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Adverse effects; Antiretroviral therapy; Hepatitis C virus; Hepatotoxicity; HIV; Nevirapine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; NEVIRAPINE; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; DRUG INDUCED DISEASE; FEMALE; HEPATITIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035816360     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107060-00007     Document Type: Article

References (24)

1. Adverse effects of antiretroviral therapy
2. Mortality for liver disease in patients with HIV infection: A cohort study
3. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
4. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
5. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
6. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
7. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor-sparing antiretroviral strategies versus a standard protease inhibitor-containing regimen, 48 week data
8. The effects of underlying renal or hepatic dysfunction on the pharmacokinetics of nevirapine
9. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
10. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral therapy
11. Assessment of hepatic cytolysis in patients switched from a protease inhibitor containing regimen to a non nucleoside reverse transcriptase containing regimen
12. Nevirapine and liver hepatotoxicity: Relevance in clinical practice
13. Hepatotoxicity of non nucleoside analogues: Nevirapine versus efavirenz
14. Hepatotoxicity of non-nucleoside reverse transcriptase inhibitor containing regimens
15. Hepatic safety with nevirapine and two nucleosides in patients with advanced HIV infection from a placebo-controlled clinical end-point trial (1090)
16. Nevirapine-induced hepatitis treated with corticosteroids?
17. Nevirapine-induced fulminant hepatitis: Presentation of case and analysis of risk factors
18. Severe hepatic failure related to nevirapine treatment
19. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor
20. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 healthcare workers
21. Recent developments in treatment-associated adverse events
22. Immunotoxicology of the liver: Adverse reactions to drugs